Abatacept now available on NHS for rheumatoid arthritis

NICE has overturned its original decision to reject the rheumatoid arthritis treatment abatacept (Orencia).

Abatacept inhibits the activation of T cells, a key step in the development of rheumatoid arthritis.
Abatacept inhibits the activation of T cells, a key step in the development of rheumatoid arthritis.

In a review of its 2008 guidance, the institute has ruled that abatacept, in combination with methotrexate, can be considered for adults with severe active rheumatoid arthritis who are unresponsive or intolerant to a DMARD (including at least one TNF inhibitor) and in whom rituximab is unsuitable.

Adalimumab, etanercept and infliximab are recommended as other treatment options alongside abatacept.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

NICE overturns advice to increase steroid dose in children with asthma

NICE overturns advice to increase steroid dose in children with asthma

NICE has withdrawn its recommendation to quadruple...

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

New antibiotic guidance for leg ulcer infection

New antibiotic guidance for leg ulcer infection

NICE has issued guidance on antibiotic choices and...

New insertion site for Nexplanon following safety concerns

New insertion site for Nexplanon following safety concerns

The MHRA has amended its advice relating to the long-acting...